Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis
Status:
Terminated
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
The is a double-blind, placebo-controlled, randomized, and multicenter study consisting of a
first treatment (FT) period followed by either an observation (OB) period and a re-treatment
(RT) period or an open-label (OL) treatment period, depending on FT period response, and a
4-week safety follow-up (FU) period. The purpose of this study is to evaluate the safety and
efficacy of onercept, to be administered as 150 milligram (mg) three times a week, compared
to matching placebo, for the induction of remission in subjects with moderate to severe
plaque psoriasis.